Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYH2053 Injection in Primary Hypercholesterolemia and Mixed Dyslipidemia (China, Phase III)
CTR20260564Phase 3Active
- Sponsor
- CSPC Zhongnuo Pharmaceutical
- Start
- Mar 2026
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of SYH2053 in hypercholesterolemia, combined dyslipidaemia, sponsored by CSPC Zhongnuo Pharmaceutical. Started Mar 2026; status: active.
02
Drugs
SYH2053
03
Conditions
hypercholesterolemiacombined dyslipidaemia
Beyond the preview
Go deeper on CTR20260564.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260564.